

In the Claims:

Please amend the claims as shown:

1. (currently amended) A peptide having a sequence comprising or consisting of QPLALEGSLQK (SEQ ID NO: 9).
2. (currently amended) A peptide selected from the group consisting of GGGPGAGSLQPLALEGSLQK (SEQ ID NO: 4), GSLQPLALEGSLQKRGIV (SEQ ID NO: 5), and QPLALEGSLQKRGIVEQ (SEQ ID NO: 6).
3. (currently amended) The peptide having the sequence GSLQPLALEGSLQKRGIV (SEQ ID NO: 5).
4. (currently amended) The peptide having the sequence GGGPGAGSLQPLALEGSLQKRGIVEQ (SEQ ID NO: 10).
5. (currently amended) A peptide according to any of claims 1 to 4, in combination with one or more peptides having a sequence selected from LAKEWQALCAYQAEPNTCATAQGEGNIK (SEQ ID NO: 11), KLVVESSPSRSDYINASPIIEHDP (SEQ ID NO: 12), and SFYLKNVQTQETRRLTQFHF (SEQ ID NO: 13).
6. (original) A peptide or peptide combination according to any of the preceding claims, comprising a peptide or peptides differing from those specified by up to and including 4 amino acid alterations (substitution and/or deletion and/or insertion) or one which is extended from any one of the above-mentioned residues at the N-terminus or C-terminus or both with one or more non-wild-type amino acid sequences.
7. (original) A peptide according to any of claims 1-6 in combination with either
 - a. IA-2 752-75
 - b. IA-2 853-72
 - c. IA-2 709-36
 - d. IA-2 752-75 and IA-2 853-72
 - e. IA-2 709-36 and IA-2 752-75

- f. IA-2 709-36 and IA-2 853-72, or
 - g. IA-2 709-36 and IA-2 752-75 and IA-2 853-72
8. (original) A pharmaceutical composition comprising a peptide or peptide combination according to any of claims 1 to 7, for the therapy of Type 1 diabetes.
 9. (original) A pharmaceutical composition according to claim 8, in which the peptide or each peptide is conjugated or otherwise combined with a tolerance-promoting adjuvant or tolerance promoting cells.
 10. (original) A diagnostic method or kit for diagnosis of, or determination of a predisposition to, Type 1 diabetes, comprising a peptide or peptide combination according to any of the preceding claims.
 11. (original) A method of treatment or prevention of Type 1 diabetes, in which a peptide or combination of peptides according to any of claims 1 to 7 is administered by parenteral or oral or topical routes, including intradermal, subcutaneous or intravenous injection, or nasally or orally or epicutaneously..
 12. (original) A method according to claim 11, in which the peptide or each peptide in a combination of peptides is administered in an amount of up to about 1mg or more per single dose.
 13. (original) A method according to claim 12, in which the peptide or each peptide in a combination of peptides is administered in an amount of from about 0.5 to about 500 micrograms or more per single dose.
 14. (original) A method according to claim 13, in which a single dose contains from 5 to 250 μ g of the, or each, peptide e.g. 5, 50, or 250 μ g.
 15. (original) A method according to any of claims 10 to 14, in which the peptide or combination is administered in conjunction with a tolerance-promoting adjuvant or tolerance promoting cells.